Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists

Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists

US Patent 9895441 · Granted Feb 20, 2018

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Antibodies, activatable antibodies, bispecific antibodies, and bispecific activa2025
HER-2 targeted bispecific compositions and methods for making and using the same2025
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activa2024
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and 2023
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activa2022
Multispecific antibodies, multispecific activatable antibodies and methods of us2021
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and 2020
Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitor2020
Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitor2020
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibit2020
Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibit2020
Anti-PD-L1 antibodies, compositions and articles of manufacture2018